Axsome posts positive results with Symbravo in migraine

24 February 2025

US CNS-focused biopharma firm Axsome Therapeutics (Nasdaq: AXSM) today announced that the EMERGE Phase III trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint.

Symbravo demonstrated statistically-significantly greater migraine treatment response compared to oral CGRP inhibitors, as measured by the migraine treatment optimization questionnaire (mTOQ-4). Symbravo is a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack. In the trial, the drug rapidly and substantially improved migraine pain and most bothersome symptoms.

Just last month, Axsome Therapeutics won US Food and Drug Administration (FDA) approval for Symbravo. However, investors were not impressed with the latest clinical data, and the firm’s shares fell more than 5% to $130.68 on the news.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK